MediGene AG – Product Pipeline Review

Global Markets Direct’s, ‘MediGene AG – Product Pipeline Review – 2016’, provides an overview of the MediGene AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by MediGene AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of MediGene AG

The report provides overview of MediGene AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses MediGene AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features MediGene AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate MediGene AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for MediGene AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding MediGene AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

MediGene AG Snapshot 5

MediGene AG Overview 5

Key Facts 5

MediGene AG - Research and Development Overview 6

Key Therapeutic Areas 6

MediGene AG - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Out-Licensed Products 11

Out-Licensed Products/Combination Treatment Modalities 12

MediGene AG - Pipeline Products Glance 13

MediGene AG - Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

MediGene AG - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

MediGene AG - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

MediGene AG - Unknown Stage Pipeline Products 18

Unknown Products/Combination Treatment Modalities 18

MediGene AG - Drug Profiles 19

Cellular Immunotherapy 1 for Oncology - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Cellular Immunotherapy 2 for Oncology - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Cellular Immunotherapy for Acute Myeloblastic Leukemia - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Cellular Immunotherapy for Multiple Myeloma - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Cellular Immunotherapy for Oncology - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Cellular Immunotherapy to Target hTERT and Survivin for Prostate Cancer - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Cellular Immunotherapy to Target MAGE-A1 for Multiple Myeloma - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Cellular Immunotherapy to Target Opa-Interacting Protein 4 and Wilm's Tumor 1 for Acute Myeloblastic Leukemia - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

human papillomavirus [serotypes 16, 31] (virus like particle) vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Monoclonal Antibodies to Target TCR for Autoimmune Disease and T-Cell Leukemia - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

RhuDex - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

sinecatechins - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

MediGene AG - Pipeline Analysis 34

MediGene AG - Pipeline Products by Target 34

MediGene AG - Pipeline Products by Route of Administration 35

MediGene AG - Pipeline Products by Molecule Type 36

MediGene AG - Pipeline Products by Mechanism of Action 37

MediGene AG - Dormant Projects 38

MediGene AG - Discontinued Pipeline Products 39

Discontinued Pipeline Product Profiles 39

etomoxir 39

Monoclonal Antibody for Ovarian Cancer 39

MediGene AG - Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

MediGene AG, Key Facts 5

MediGene AG – Pipeline by Indication, 2016 8

MediGene AG – Pipeline by Stage of Development, 2016 9

MediGene AG – Monotherapy Products in Pipeline, 2016 10

MediGene AG – Out-Licensed Products in Pipeline, 2016 11

MediGene AG – Out-Licensed Products/ Combination Treatment Modalities, 2016 12

MediGene AG – Phase III, 2016 13

MediGene AG – Phase II, 2016 14

MediGene AG – Phase I, 2016 15

MediGene AG – Preclinical, 2016 16

MediGene AG – Discovery, 2016 17

MediGene AG – Unknown, 2016 18

MediGene AG – Pipeline by Target, 2016 34

MediGene AG – Pipeline by Route of Administration, 2016 35

MediGene AG – Pipeline by Molecule Type, 2016 36

MediGene AG – Pipeline Products by Mechanism of Action, 2016 37

MediGene AG – Dormant Developmental Projects,2016 38

MediGene AG – Discontinued Pipeline Products, 2016 39

MediGene AG, Subsidiaries 40

List of Figures

List of Figures

MediGene AG – Pipeline by Top 10 Indication, 2016 7

MediGene AG – Pipeline by Stage of Development, 2016 9

MediGene AG – Monotherapy Products in Pipeline, 2016 10

MediGene AG – Out-Licensed Products in Pipeline, 2016 11

MediGene AG – Pipeline by Target, 2016 34

MediGene AG – Pipeline by Route of Administration, 2016 35

MediGene AG – Pipeline by Molecule Type, 2016 36

MediGene AG – Pipeline Products by Mechanism of Action, 2016 37

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports